Clinical trial
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late…
NCT00447993 · Neurotech Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00447993 |
|---|---|
| Title | A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa |
| Official title | A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Acuity as the Primary Outcome |
| Lead sponsor | Neurotech Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Retinitis Pigmentosa |
| Intervention type | Combination Product |
| Interventions | Low Dose NT-501, High Dose NT-501 |
| Enrollment | 67 |
| Start date | Jan 8, 2007 |
| Primary completion | May 26, 2009 |
| Completion | May 26, 2009 |
| First posted | Mar 15, 2007 |
| Last update posted | Aug 13, 2024 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: